Biogen exec sells 748 shares after RSU vesting

Biogen Inc.’s Head of Development, Priya Singhal, reported equity transactions involving company stock.

Accepted by SEC EDGAR 02/03/2026 - 05:17 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Biogen Inc.’s Head of Development, Priya Singhal, reported equity transactions involving company stock. On January 30, 2026, 1,829 shares of common stock were acquired at $0 following the vesting and exercise of a restricted stock unit award granted on February 1, 2023 that vests in three equal annual installments.

Also on January 30, 2026, 582 shares were surrendered at $179.89, and on February 2, 2026, 748 shares were sold at $179.3. After these transactions, Singhal directly held 6,271.1428 shares of Biogen common stock.

Insider Trade Summary

Exercise and sale activity reported; no spread calculated

Exercise and Sale 4 txns

Insider Singhal Priya

Role Head of Development

Sold 748 shs ($134K)

Approx. gross sale proceeds $134K

Approx. exercise cost $0.00

Share of Position Sold 10.7%

Type	Security	Shares	Price	Value
Sale	Common Stock	748	$179.30	$134K
Exercise	Restricted Stock Unit	1,829	$0.00	$0.00
Exercise	Common Stock	1,829	$0.00	$0.00
Exercise Price or Tax Liability	Common Stock	582	$179.89	$105K

Holdings After Transaction: Restricted Stock Unit — 0 contracts (Direct); Common Stock — 6,271.1428 shares (Direct)

Holdings Before and After: Restricted Stock Unit, 1,829 to 0 contracts (Direct); Common Stock, 5,772.1428 to 6,271.1428 shares (Direct)

Footnotes (1)

1. F1. This award was granted to the reporting person on February 1, 2023 and will vest in three equal installments on each anniversary of the grant date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Biogen (BIIB) report for Priya Singhal?

Biogen reported that Head of Development Priya Singhal sold 748 shares of common stock at $179.3 on February 2, 2026, following earlier equity transactions on January 30, 2026, including the vesting and exercise of 1,829 restricted stock units.

How many Biogen (BIIB) shares does Priya Singhal hold after the Form 4?

After the reported Form 4 transactions, Priya Singhal directly holds 6,271.1428 shares of Biogen common stock. This figure reflects the net position following RSU vesting, share surrender related to that vesting, and the subsequent sale of 748 shares.

What equity award activity did Biogen (BIIB) disclose for Priya Singhal?

Biogen disclosed that 1,829 restricted stock units granted on February 1, 2023 converted into 1,829 shares of common stock at a $0 exercise price on January 30, 2026. The award vests in three equal installments on each anniversary of the grant date.

Why were 582 Biogen (BIIB) shares reported with code "F" on the Form 4?

The Form 4 shows 582 Biogen common shares with transaction code "F" at $179.89 on January 30, 2026. Code "F" indicates shares were withheld or surrendered, typically to cover tax obligations arising from the vesting of equity awards such as restricted stock units.

What position does Priya Singhal hold at Biogen (BIIB) in this Form 4?

In this Form 4, Priya Singhal is identified as an officer of Biogen with the title "Head of Development." The filing confirms she is not listed as a director or 10% owner, and the reported holdings are shown as directly owned common stock.

When does Priya Singhal’s Biogen (BIIB) RSU award vest?

The RSU award to Priya Singhal was granted on February 1, 2023 and will vest in three equal installments on each anniversary of that grant date. One such installment vested on January 30, 2026, resulting in the conversion of 1,829 units to common shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Singhal Priya

(Last) (First) (Middle)

225 BINNEY

(Street)

CAMBRIDGE MA 02142

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BIOGEN INC. [ BIIB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Head of Development

3. Date of Earliest Transaction (Month/Day/Year)
01/30/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/30/2026		M		1,829	A	$0	7,601.1428	D
Common Stock	01/30/2026		F		582	D	$179.89	7,019.1428	D
Common Stock	02/02/2026		S		748	D	$179.3	6,271.1428	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Unit	$0	01/30/2026		M			1,829	(1)	02/01/2026	Common Stock	1,829	$0	0	D

Explanation of Responses:

1. This award was granted to the reporting person on February 1, 2023 and will vest in three equal installments on each anniversary of the grant date.

	/s/ Wendell Taylor, attorney-in-fact for Priya Singhal	02/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.